MedTrace Logo

A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure

NCT03443843 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2019-12-20

No results posted yet for this study

Summary

The purpose of the study is to evaluate changes in nasal airflow caused by loratadine 5 mg/pseudoephedrine sulfate 120 mg (Claritin D) tablet and fluticasone propionate 50 mcg per spray nasal spray (Flonase) in subjects suffering from nasal congestion and other allergy symptoms.

Conditions

  • Rhinitis, Allergic

Interventions

DRUG

loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D)

Single dose of Loratadine/pseudoephedrine in tablet 5 mg/120 mg orally

DRUG

Placebo tablet

Placebo tablet orally

DRUG

Fluticasone Propionate

Fluticasone Propionate Nasal Spray 50mcg per spray, 2 sprays per nostril

DRUG

Placebo spray

Placebo Nasal Spray, 2 sprays per nostril

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-21
Primary Completion
2018-05-11
Completion
2018-05-11

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03443843 on ClinicalTrials.gov